Amicus Therapeutics Plunges 14.06% on Earnings Miss
Amicus Therapeutics' stock price plummeted by 14.06% in pre-market trading on May 1, 2025, marking a significant decline for the biopharmaceutical company.
Amicus Therapeutics reported its first-quarter 2025 financial results, revealing a total revenue of $125.2 million, which represents a 15% year-over-year increase at constant exchange rates. This growth was driven by strong sales of Galafold, which contributed $104.2 million to the total revenue. However, the company reported a net loss of $21.7 million for the quarter, which may have contributed to the stock's decline.
The company also announced the expansion of its portfolio through the in-licensing of the DMX-200 Phase 3 program for rare kidney diseases. This strategic move is aimed at enhancing Amicus Therapeutics' position in the rare disease treatment market, but investors may be cautious about the potential risks and uncertainties associated with the development of new therapies.
Despite the revenue growth, Amicus Therapeutics' earnings and revenue surprises for the quarter were -62.50% and 7.66%, respectively. This indicates that the company's performance fell short of analysts' expectations, which may have further dampened investor sentiment. The company's revenue for the quarter also fell short of the estimated $135.86 million, which may have contributed to the stock's decline.
































































































































































